OneSource Specialty Pharma LimitedNSE: ONESOURCE

Press Release Apr 29 2026

· Issued by OneSource Specialty Pharma Limited

Filed with NSE · · 2 pages · English

Summary by 6ix AI

OneSource Specialty Pharma Limited issued a press release regarding a significant development with its partner, Dr. Reddy's Laboratories, which has received Health Canada approval for a generic Semaglutide injection. OneSource serves as the manufacturing partner, providing scale-up and commercial manufacturing support for this product.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Onesource Specialty Pharma Limited has informed the Exchange regarding a press release dated April 29, 2026, titled "OneSource s Partner Dr. Reddy's Laboratories receives Health Canada Approval for Generic Semaglutide Injection".

OneSource Specialty Pharma Limited on 6ix

Earlier from OneSource Specialty Pharma

Later from OneSource Specialty Pharma

All OneSource Specialty Pharma news releases